Overview: Allergy Candida Albicans TestIntroduction: The Allergy Candida Albicans Test detects IgE antibodies to Candida albicans, a yeast that may cause skin rashes, itching, or respiratory issues. Aligned with 2023 AAAAI guidelines, it uses an immunoassay for high sensitivity, aiding in confirming yeast allergies. This test is critical for guiding avoidance strategies or antifungal therapy, preventing allergic reactions, and improving outcomes in allergology.
Other Names: Allergy Candida Assay, Candida Albicans IgE Test.
FDA Status: Laboratory-developed test (LDT) meeting allergology standards for diagnostic accuracy.
Historical Milestone: Yeast allergy testing began in the 1980s with skin tests. Specific IgE immunoassays emerged in the 1990s, and by the 2000s, advanced assays improved specificity for Candida allergens.
Purpose: Diagnoses Candida albicans allergies, guides avoidance or therapy, and monitors allergic responses in patients with skin or respiratory symptoms.
Test Parameters: 1. Candida Albicans IgE
Pretest Condition: No fasting required. Collect serum or saliva at any time, preferably during symptom onset or yeast exposure. Report symptoms like rashes, itching, or respiratory issues, and list medications like antihistamines.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document allergic symptoms, yeast exposure history, or family history of allergies or asthma. Include current medications, especially antihistamines or antifungals.
Consent: Written consent required, explaining the tests purpose, diagnostic implications, and potential need for avoidance or antifungal therapy.
Procedural Considerations: Uses an immunoassay to measure Candida-specific IgE. Results are available in 1-2 days, supporting rapid diagnosis.
Factors Affecting Result Accuracy: Antihistamines or antifungals may suppress IgE levels, causing false negatives. Hemolysis or improper storage can degrade samples. Testing during low yeast exposure may reduce sensitivity.
Clinical Significance: Elevated Candida-specific IgE confirms allergy, prompting avoidance or antifungal therapy. Normal levels may require skin testing for confirmation.
Specialist Consultation: Consult an allergist for result interpretation. Infectious disease referral is advised for suspected yeast overgrowth.
Additional Supporting Tests: Skin prick test, total IgE, or fungal panel to confirm Candida allergy or identify cross-reactive allergens.
Test Limitations: False negatives may occur with antihistamine use or low yeast exposure. Cross-reactivity with other fungi requires clinical correlation.
References: AAAAI Allergy Guidelines, 2023; Clinical Infectious Diseases, Pappas PG, 2022.
